Screener
Janux Therapeutics JANX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from financing activities | ||
| Proceeds from exercise of common stock options and employee stock purchase plan | 5,785 | 1,855 |
| Payments of issuance costs | — | (347) |
| Net cash provided by financing activities | 5,785 | 1,508 |
| Net decrease in cash, cash equivalents and restricted cash | (24,566) | (378,159) |
| Cash, cash equivalents and restricted cash – beginning of year | 53,150 | 431,421 |
| Cash, cash equivalents and restricted cash – end of period | $28,584 | $53,262 |
| Supplemental disclosure of noncash investing and financing activities |
Item 1. Financial Statements.
FAQ
- What is Janux Therapeutics's financing cash flow?
- Janux Therapeutics (JANX) reported financing cash flow of $2.24M in Q2 2026.
- How has Janux Therapeutics's financing cash flow changed year-over-year?
- Janux Therapeutics's financing cash flow increased by 134.8% year-over-year, from $954K to $2.24M.
- What is the long-term trend for Janux Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Janux Therapeutics's financing cash flow has grown at a -66.4% compound annual growth rate (CAGR), from $387.37M to $4.95M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Janux Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude